New insider activity at Immunovant ( (IMVT) ) has taken place on October 24, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Immunovant stock, CTO Jay S Stout sold 2,520 shares, amounting to a total sale value of $47,955. Meanwhile, CMO Michael Geffner parted with 2,595 shares, resulting in a sale worth $49,382.
Recent Updates on IMVT stock
Recent developments for Immunovant’s stock include Truist initiating coverage with a Hold rating, citing that while IMVT1402 shows potential with deeper IgG reductions compared to other FcRn inhibitors, it is considered too far behind in certain indications to gain significant market traction. This is despite the company’s strategy to pursue first-in-class indications, with meaningful de-risking not expected until 2027. Additionally, JPMorgan lowered its price target from $37 to $33, updating the company’s model. The adjustments reflect strategic considerations and market positioning rather than immediate financial performance.
Spark’s Take on IMVT Stock
According to Spark, TipRanks’ AI Analyst, IMVT is a Neutral.
Immunovant’s stock score is primarily impacted by substantial financial weaknesses, including ongoing losses and cash flow issues. Technical indicators are bearish, further weighing on the stock’s attractiveness. However, recent positive clinical trial results and leadership changes provide some optimism, potentially strengthening the company’s pipeline and long-term prospects.
To see Spark’s full report on IMVT stock, click here.
More about Immunovant
YTD Price Performance: -25.61%
Average Trading Volume: 1,616,172
Technical Sentiment Signal: Buy
Current Market Cap: $3.29B